ISIS 5132

Drug Profile

ISIS 5132

Alternative Names: CGP 69846A

Latest Information Update: 16 Sep 2002

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Protein kinase inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 16 Sep 2002 Discontinued - Phase-I for Solid tumours in USA (IV-infusion)
  • 16 Sep 2002 Discontinued - Phase-II for Small cell lung cancer in USA (unspecified route)
  • 16 Sep 2002 Discontinued - Phase-II for Ovarian cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top